Targeted therapies for kidney cancer in urologic practice

Naomi B. Haas; Robert G. Uzzo

doi:10.1016/j.urolonc.2007.05.009

Targeted therapies for kidney cancer in urologic practice

Naomi B. Haas, Robert G. Uzzo

Temple University

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.

Original language	English
Pages (from-to)	420-432
Number of pages	13
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	25
Issue number	5
DOIs	https://doi.org/10.1016/j.urolonc.2007.05.009
State	Published - Sep 2007

Keywords

Angiogenesis
Cancer
Kidney
Renal
Targeted therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.urolonc.2007.05.009

Cite this

@article{a2c3cf8c1a224d739967a2adc44941c0,

title = "Targeted therapies for kidney cancer in urologic practice",

abstract = "Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.",

keywords = "Angiogenesis, Cancer, Kidney, Renal, Targeted therapy",

author = "Haas, {Naomi B.} and Uzzo, {Robert G.}",

year = "2007",

month = sep,

doi = "10.1016/j.urolonc.2007.05.009",

language = "English",

volume = "25",

pages = "420--432",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Targeted therapies for kidney cancer in urologic practice

AU - Haas, Naomi B.

AU - Uzzo, Robert G.

PY - 2007/9

Y1 - 2007/9

N2 - Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.

AB - Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.

KW - Angiogenesis

KW - Cancer

KW - Kidney

KW - Renal

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=34548419260&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2007.05.009

DO - 10.1016/j.urolonc.2007.05.009

M3 - Review article

C2 - 17826664

SN - 1078-1439

VL - 25

SP - 420

EP - 432

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 5

ER -

Targeted therapies for kidney cancer in urologic practice

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this